Common and discriminative clinicopathological features between breast cancers with pathological complete response or progressive disease in response to neoadjuvant chemotherapy.
OBJECTIVE
To clarify clinicopathological similarities and differences between breast carcinomas that achieve pathological complete response (pCR) to neoadjuvant chemotherapy (NAC) and those showing progressive disease (PD) during NAC, we compared pre-NAC clinicopathological characteristics between these tumors.


METHODS
Subjects comprised 32 patients (6%) achieved pCR and 33 patients (7%) showed PD of 494 patients (498 breasts) with stage II or III breast carcinoma who underwent anthracycline-based or taxane chemotherapy or both, followed by surgery, between 2000 and 2006. We compared patient characteristics before NAC, and histomorphology, immunohistochemistry, and molecular subtypes of tumors using pre-NAC biopsy samples. Immunohistochemistry included estrogen receptor (ER), progesterone receptor (PgR), human epidermal growth factor receptor-2 (HER2), epidermal growth factor receptor (EGFR), cytokeratin 5/6 (CK5/6). Molecular subtypes were defined by ER, PgR, HER2, EGFR, and CK5/6. We compared these factors between pCR and PD using univariate chi (2) testing and multivariate logistic regression analyses.


RESULTS
No significant differences between groups were seen regarding NAC regimens. Solid-tubular carcinoma (53% of pCR, 61% of PD), histological grade 3 (78% of pCR, 79% of PD), ER-status (91% of pCR, 82% of PD), and basal-like subtype (44% of pCR, 58% of PD) were often observed in both groups. In multivariate analyses, lower clinical N stage at diagnosis (P = 0.004) and HER2/ER-PgR- subtype (P = 0.020) were significantly associated with pCR.


CONCLUSIONS
Breast carcinomas achieving pCR or showing PD with NAC have common peculiar characteristics such as solid-tubular carcinoma, high grade, hormone receptor negativity, and basal-like subtype. Conversely, discriminative factors include clinical N stage at diagnosis and HER2/ER-PgR- subtype.
Osako
Tomo
T
Division of Pathology, Cancer Institute Hospital of the Japanese Foundation for Cancer Research, 3-10-6, Ariake, Koto-ku, Tokyo, 135-8550, Japan. tomo.osako@jfcr.or.jp
Horii
Rie
R
Matsuura
Masaaki
M
Ogiya
Akiko
A
Domoto
Kaoru
K
Miyagi
Yumi
Y
Takahashi
Shunji
S
Ito
Yoshinori
Y
Iwase
Takuji
T
Akiyama
Futoshi
F
D000328:Adult; D000368:Aged; D000704:Analysis of Variance; D018943:Anthracyclines / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000378:metabolism*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology*; D017024:Chemotherapy, Adjuvant; D018450:Disease Progression; D000077143:Docetaxel; D004317:Doxorubicin / Q000008:administration & dosage; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D008875:Middle Aged; D020360:Neoadjuvant Therapy / Q000379:methods*; D009367:Neoplasm Staging; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000378:metabolism; D011960:Receptors, Estrogen / Q000378:metabolism; D011980:Receptors, Progesterone / Q000378:metabolism; D043823:Taxoids / Q000008:administration & dosage; D016896:Treatment Outcome
D018943:Anthracyclines; D014408:Biomarkers, Tumor; D000077143:Docetaxel; D004317:Doxorubicin; D018719:Erb-b2 Receptor Tyrosine Kinases; D011960:Receptors, Estrogen; D011980:Receptors, Progesterone; D043823:Taxoids
J Clin Oncol. 1999 Feb;17(2):460-9
10080586
Br J Cancer. 2002 Apr 8;86(7):1041-6
11953845
J Natl Cancer Inst. 2004 Aug 4;96(15):1141-51
15292386
J Clin Oncol. 2003 Jul 1;21(13):2600-8
12829681
Breast. 2007 Dec;16 Suppl 2:S72-7
17714947
J Clin Oncol. 2006 May 1;24(13):2019-27
16606972
Cancer Res. 1990 Nov 1;50(21):7057-61
2208173
Cancer. 2007 Sep 15;110(6):1195-200
17647266
J Natl Cancer Inst Monogr. 2001;(30):96-102
11773300
Breast Cancer. 2005;12 Suppl:S1-27
16410755
Breast Cancer. 2008;15(1):5-7
18224386
Breast Cancer. 2007;14(4):393-400
17986805
Mod Pathol. 2005 Jan;18(1):26-35
15332092
BMC Cancer. 2007 Nov 01;7:203
17976237
J Clin Oncol. 2005 Jun 1;23(16):3676-85
15738535
Eur J Cancer. 2003 May;39(8):1089-96
12736108
Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8418-23
12829800
Mod Pathol. 2006 Feb;19(2):264-71
16341146
Clin Cancer Res. 2007 Apr 15;13(8):2329-34
17438091
Jpn J Clin Oncol. 2008 Feb;38(2):99-105
18270380
J Clin Oncol. 1997 Jul;15(7):2483-93
9215816
J Clin Oncol. 2001 Nov 15;19(22):4224-37
11709566
J Clin Oncol. 2002 Mar 15;20(6):1456-66
11896092
Ann Surg Oncol. 2002 Apr;9(3):228-34
11923128
Cancer. 2002 Jun 15;94(12):3107-14
12115341
J Clin Oncol. 2008 Jan 10;26(2):246-52
18056680
Clin Cancer Res. 2004 Aug 15;10(16):5367-74
15328174
Cancer. 2002 Aug 15;95(4):681-95
12209710
Chin Med J (Engl). 2008 Mar 5;121(5):387-91
18364105
J Clin Oncol. 1998 Jan;16(1):93-100
9440728
Cancer. 2005 Jun 1;103(11):2252-60
15834928
Clin Cancer Res. 2005 Aug 15;11(16):5678-85
16115903
Br J Cancer. 2003 May 6;88(9):1339-45
12778058
Gan No Rinsho. 1985 May;Suppl:105-13
2999462
Jpn J Clin Oncol. 1998 Aug;28(8):486-91
9769782
Breast Cancer Res Treat. 2008 Mar;108(2):183-90
17468948
Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10869-74
11553815
Histopathology. 1991 Nov;19(5):403-10
1757079
J Clin Oncol. 2003 Nov 15;21(22):4165-74
14559892
J Natl Cancer Inst. 2000 Feb 2;92(3):205-16
10655437
J Natl Cancer Inst. 2003 Jan 15;95(2):142-53
12529347
Clin Cancer Res. 2008 Mar 1;14(5):1368-76
18316557
Cancer Res. 2008 Aug 15;68(16):6477-81
18701468
Breast Cancer Res. 2008;10(2):R30
18380893
J Natl Cancer Inst. 2005 Feb 2;97(3):188-94
15687361
J Clin Oncol. 2005 Nov 20;23(33):8331-9
16293864
JAMA. 2006 Jun 7;295(21):2492-502
16757721
J Clin Oncol. 2008 Feb 10;26(5):778-85
18258986
J Clin Oncol. 2008 Mar 10;26(8):1275-81
18250347